Efficacy and Safety of Meloxicam (Mobicox®) in Mexican Population With Rheumatic Diseases
Completed
- Conditions
- Osteoarthritis
- Registration Number
- NCT02184039
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
Study to evaluate the efficacy and safety of meloxicam (Mobicox®) in Mexican population with rheumatic diseases.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 12687
Inclusion Criteria
- none
Exclusion Criteria
- Hypersensitivity to meloxicam or to other NSAIDS
- History of asthma, angioedema or urticaria secondary to NSAIDS
- Pregnancy or lactation
- Recent or current history of peptic ulcer disease, severe renal failure, severe hepatic failure
- Age below of 12 years.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in intensity of the symptoms measured with a four-point scale Baseline, 30 and 90 days
- Secondary Outcome Measures
Name Time Method Degree of satisfaction evaluated with a six point numerical rating scale up to 90 days Number of patients with adverse events up to 90 days